Clin Infect Dis. 2020;71(2):422-425.
Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
제1저자 김범석, 강창경 · 교신저자 박완범, 김유정
소속 (4)
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
- Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea.
Abstract
Among prospectively enrolled adult patients with cancer receiving immune checkpoint inhibitors (ICIs; n = 46) or cytotoxic agents (n = 90), seroprotection and seroconversion rates after seasonal quadrivalent influenza vaccinations were higher with ICI than with cytotoxic chemotherapy. These results support annual influenza vaccinations for cancer patients receiving ICIs. Clinical Trials Registration clinicaltrials.gov (NCT03590808).
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Keywords
immune checkpoint inhibitorimmune-related adverse eventimmunogenicityinfluenzavaccination
그 밖의 정보
- 출판 형태
- Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
- 저널
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · eISSN 1537-6591
- MeSH
- Adult · Antibodies, Viral / therapeutic use · Humans · Immune Checkpoint Inhibitors · Influenza Vaccines* / therapeutic use · Influenza, Human* / prevention & control · Neoplasms* / drug therapy · Seroconversion · Vaccination
- Substances
- Antibodies, Viral · Immune Checkpoint Inhibitors · Influenza Vaccines
- 데이터
- ClinicalTrials.gov: NCT03590808